PCN21 A Real-World Assessment of the Treatment Patterns, Healthcare Resource Utilization (HCRU) and Outcomes Associated with Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC) in the United States

To describe demographics, clinical status, treatment patterns, HCRU, quality of life (QoL), and survival outcomes of US patients with GC and GEJC. This retrospective observational study utilized the Vidence relational database incorporating linked electronic medical records, medication utilization data, patient reported outcomes data, outpatient records, surgical records, and genomic assessments of patients. Patients having ≥2 medical records with a primary ICD-9/ICD-10 diagnostic code of GC or GEJC were selected from Jan 1st, 2012 through Sept 30th,2019. The first date of a GC or GEJC record was defined as the index date. Patients were followed for at least 30 days before and after the index date. Demographics, clinical parameters, medication utilization, HCRU, QoL and outcomes were tracked in the post-index. Eligible patients with GC (n = 198) and GEJC (n= 171) were of similar mean (SD) age at index (GC, 56.4 [10.3]; GEJC, 58.2 [9.9] years), and predominantly male (GC, 53%; GEJC, 79%). The majority had disease characterized as stage 4 (GC, 54.6%; GC, 55.6%) and non-resectable (GC, 69.7%; GEJC 80.7%) at index. Most received first line (1L) chemotherapy (GC, 69.2%; GEJC, 77.2%) and roughly half went on from 1L to 2L treatment (GC, 47.4%; GEJC, 56.8%). 49.2 % GC and 40% GEJC) of 2L patients received 3L treatment. Patients with GC and GEJC had the same overall survival (39%) and a similar median (95% CI) survival (GC, 15.2 [12.6-19.8]; GEJC, 16 [13.3-20.1] months ) over the post-index observation period and similar frequency of distant metastatic disease post-index (GC, 83.8%; GEJC, 84.8%). Median survival for patients with GC and GEJC was slightly over 15 months, with overall survival for both at 39%. These findings reflect a high unmet need for novel and more effective treatment approaches.